Skip to main content
SpringerLink
Log in

Neues zur symptomatischen MS-Therapie: Teil 5 – Fatigue

New aspects of symptomatic MS treatment: Part 5 – fatigue

  • Aktuelles
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Die symptomatische Behandlung der multiplen Sklerose (MS) hat heutzutage neben der Immuntherapie einen hohen Stellenwert im umfassenden Therapiekonzept dieser chronischen Erkrankung, trägt sie doch erheblich zu einer Verringerung von Beeinträchtigungen im Alltag, sozialen und beruflichen Leben sowie zur Verbesserung der Lebensqualität bei. Seit der letzten umfassenden Bestandsaufnahme 2004 in dieser Zeitschrift sowie den Leitlinien der DGN(Deutschen Gesellschaft für Neurologie)/KKN-MS(Klinisches Kompetenznetz Multiple Sklerose) zu Diagnose und Therapie der MS 2014 haben sich Neuerungen und Ergänzungen in den Bereichen Mobilität, Blasenfunktion, Sexualfunktionen, Augen, Fatigue, Kognition und Rehabilitation ergeben. Diese sowie weitere Aspekte (Messmethoden des jeweiligen Symptoms, Therapieziele, Gesamtbehandlungsplan) werden in einer Reihe aus 6 Einzelbeiträgen vorgestellt. Hier soll auf die Fatigue eingegangen werden.

Abstract

The symptomatic treatment of multiple sclerosis (MS) is nowadays of similar importance as immunotherapy within a comprehensive treatment concept of this chronic disease. It makes a considerable contribution to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of the quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Clinical Competence Network Multiple Sclerosis (Klinisches Kompetenznetz Multiple Sklerose, KKN-MS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation have taken place. These new findings together with further aspects of disease measurement methods and overall treatment strategies of the respective symptoms as well as treatment goals are introduced in a series of 6 individual contributions. In this article the symptom of fatigue is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Henze T, Rieckmann P, Toyka KV (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75((Supp.1):2–39

    PubMed  Google Scholar 

  2. Mathiowetz V (2003) Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. Am J Occup Ther 57:389–395

    Article  PubMed  Google Scholar 

  3. Penner IK, Raselli C, Stocklin M et al (2009) The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 15:1509–1517

    Article  CAS  PubMed  Google Scholar 

  4. Flachenecker P (2015) Fatigue bei Multipler Sklerose. Diagnostische und therapeutische Aspekte. Nervenheilkunde 34:685–689

    Article  Google Scholar 

  5. Flachenecker P, Kümpfel T, Kallmann B et al (2002) Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 8:523–526

    Article  CAS  PubMed  Google Scholar 

  6. Khan F, Amatya B, Galea M (2014) Management of fatigue in persons with multiple sclerosis. Front Neurol 5:177

    Article  PubMed  PubMed Central  Google Scholar 

  7. Flachenecker P (2012) Autoimmune diseases and rehabilitation. Autoimmun Rev 11:219–225

    Article  PubMed  Google Scholar 

  8. Sehle A, Vieten M, Sailer S et al (2014) Objective assessment of motor fatigue in multiple sclerosis: the Fatigue index Kliniken Schmieder (FKS). J Neurol 261:1752–1762

    Article  PubMed  Google Scholar 

  9. Asano M, Finlayson ML (2014) Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. https://doi.org/10.1155/2014/798285

  10. Heine M, van de Port I, Rietberg MB et al (2015) Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009956

    PubMed  Google Scholar 

  11. Kos D, Duportail M, D’hooghe M et al (2007) Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult Scler 13:996–1003

    Article  CAS  PubMed  Google Scholar 

  12. Finlayson M, Preissner K, Cho C et al (2011) Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Mult Scler 17:1130–1140

    Article  PubMed  Google Scholar 

  13. Latimer-Cheung AE, Pilutti LA, Hicks AL et al (2013) Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil 94:1800–1828

    Article  PubMed  Google Scholar 

  14. Thomas S, Thomas PW, Kersten P et al (2013) A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1092–1099

    Article  PubMed  PubMed Central  Google Scholar 

  15. Blikman LJ, Huisstede BM, Kooijmans H et al (2013) Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil 94:1360–1376

    Article  PubMed  Google Scholar 

  16. Thomas PW, Thomas S, Kersten P et al (2014) One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. BMC Neurol 14:109

    Article  PubMed  PubMed Central  Google Scholar 

  17. van Kessel K, Moss-Morris R, Willoughby E et al (2008) A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 70:205–213

    Article  PubMed  Google Scholar 

  18. Moss-Morris R, McCrone P, Yardley L et al (2012) A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue. Behav Res Ther 50:415–421

    Article  PubMed  Google Scholar 

  19. Simpson R, Booth J, Lawrence M et al (2014) Mindfulness based interventions in multiple sclerosis — a systematic review. BMC Neurol 14:15

    Article  PubMed  PubMed Central  Google Scholar 

  20. Guner S, Inanici F (2015) Yoga therapy and ambulatory multiple sclerosis assessment of gait analysis parameters, fatigue and balance. J Bodyw Mov Ther 19:72–81

    Article  PubMed  Google Scholar 

  21. NASA MS Cooling Study Group (2003) A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 60:1955–1960

    Article  Google Scholar 

  22. Khan F, Turner-Stokes L, Ng L et al (2007) Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858

    Google Scholar 

  23. Storr LK, Sorensen PS, Ravnborg M (2006) The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Mult Scler 12:235–242

    Article  CAS  PubMed  Google Scholar 

  24. de Carvalho ML, Motta R, Konrad G et al (2012) A randomized placebo-controlled cross-over study using a low frequency magnetic field in the treatment of fatigue in multiple sclerosis. Mult Scler 18:82–89

    Article  PubMed  Google Scholar 

  25. Haase R, Piatkowski J, Ziemssen T (2011) Long-term effects of bio-electromagnetic-energy regulation therapy on fatigue in patients with multiple sclerosis. Altern Ther Health Med 17:22–28

    PubMed  Google Scholar 

  26. Tomassini V, Pozzilli C, Onesti E et al (2004) Comparison of the effects of acetyl L‑carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 218:103–108

    Article  CAS  PubMed  Google Scholar 

  27. Ledinek AH, Sajko MC, Rot U (2013) Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis — result of a pilot randomized, blind study. Clin Neurol Neurosurg 115(Suppl 1):S86–89

    Article  PubMed  Google Scholar 

  28. Lebrun C, Alchaar H, Candito M et al (2006) Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 12:321–324

    Article  CAS  PubMed  Google Scholar 

  29. Etemadifar M, Sayahi F, Abtahi SH et al (2013) Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. Int J Neurosci 123:480–486

    Article  PubMed  Google Scholar 

  30. Achiron A, Givon U, Magalashvili D et al (2015) Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Mult Scler 21:767–775

    Article  CAS  PubMed  Google Scholar 

  31. Shaygannejad V, Janghorbani M, Ashtari F et al (2012) Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res 34:854–858

    Article  CAS  PubMed  Google Scholar 

  32. Mucke M, Cuhls H, Peuckmann-Post V et al (2015) Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006788

    PubMed  Google Scholar 

  33. Möller F, Poettgen J, Broemel F et al (2011) HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler 17:1002–1009

    Article  PubMed  Google Scholar 

  34. Goodman AD, Cohen JA, Cross A et al (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13:357–368

    Article  CAS  PubMed  Google Scholar 

  35. Goodman AD, Brown TR, Krupp LB et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732–738

    Article  CAS  PubMed  Google Scholar 

  36. Pucci E, Branas P, D’Amico R et al (2007) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002818

    PubMed  Google Scholar 

  37. Brown JN, Howard CA, Kemp DW (2010) Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 44:1098–1103

    Article  CAS  PubMed  Google Scholar 

Download references

Danksagung

Wir bedanken uns bei der Firma Almirall Hermal für finanzielle Hilfe bei der technischen Erstellung des Manuskripts, ebenso bei Frau Dr. U. Essner sowie Frau Dr. P. Hundehege und Frau L. Forster (Neurologische Universitätsklinik Münster) für ihre Hilfe bei der Erstellung des Manuskripts.

Author information

Authors and Affiliations

  1. Praxisgemeinschaft für Neurologie, Psychiatrie, Psychotherapie, Günzstr. 1, 93059, Regensburg, Deutschland

    T. Henze

  2. Department für Neurologie und Institut für Translationale Neurologie, Klinik für Allgemeine Neurologie, Universitätsklinikum, Münster, Deutschland

    S. G. Meuth

  3. Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Deutschland

    W. Feneberg & M. Starck

  4. Neurologisches Rehabilitationszentrum Quellenhof, Bad Wildbad, Deutschland

    P. Flachenecker

  5. Bocholt, Deutschland

    D. Seidel

  6. Praxis für Neurologie, München, Deutschland

    H. Albrecht

Authors
  1. T. Henze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Feneberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Flachenecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Seidel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Albrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Starck
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. G. Meuth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Henze.

Ethics declarations

Interessenkonflikt

T. Henze erhielt Vortragshonorare und Aufwandsentschädigungen für Advisory Boards von Almirall, Coloplast, Genzyme, Novartis, Sanofi. Interessenkonflikte bestehen nicht. W. Feneberg erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen von Almirall, Bayer, Biogen Idec, Coloplast, Genzyme, Ipsen, Merz, Novartis, Sanofi-Aventis. Interessenkonflikte bestehen nicht. P. Flachenecker hat Honorare für Vorträge und Beratungstätigkeiten von den Firmen Almirall, Bayer, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche und Teva erhalten und an industriegesponsorten Studien von Biogen Idec und Novartis teilgenommen. Interessenkonflikte bestehen nicht. H. Albrecht hat Zahlungen für Reisekosten und/oder Fortbildungsveranstaltungen und/oder Studien erhalten von Almirall, Bayer Healthcare, Biogen Idec, Genzyme-Sanofi, Merck Serono, Teva. S.G. Meuth erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen und/oder Projektförderung von Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis und Teva. D. Seidel und M. Starck geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Weitere Beiträge dieser Beitragsserie, die ebenfalls in Der Nervenarzt publiziert wurden, befassen sich mit den Themen Einleitung und methodisches Vorgehen, Ataxie und Tremor (https://doi.org/10.1007/s00115-017-0438-4), Gangstörung und Spastik (https://doi.org/10.1007/s00115-017-0439-3), Blasenfunktionsstörungen (https://doi.org/10.1007/s00115-017-0440-x), Störungen der Sexualfunktion und der Augenbewegungen (https://doi.org/10.1007/s00115-017-0441-9), sowie mit den kognitiven Störungen und der Rehabilitation (https://doi.org/10.1007/s00115-017-0443-7).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henze, T., Feneberg, W., Flachenecker, P. et al. Neues zur symptomatischen MS-Therapie: Teil 5 – Fatigue. Nervenarzt 89, 446–452 (2018). https://doi.org/10.1007/s00115-017-0442-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-017-0442-8

Schlüsselwörter

Keywords

Search

Navigation